Author | Ajay S. Behl, PhD | OncLive

Author | Ajay S. Behl, PhD


CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

July 19, 2016

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.